Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
NPJ Microgravity ; 8(1): 18, 2022 Jun 02.
Artigo em Inglês | MEDLINE | ID: mdl-35654945

RESUMO

Alpha(α)Klotho, a soluble transmembrane protein, facilitates calcium-phosphorus homeostasis through feedback between bone and kidney and is a potential systemic biomarker for bone-kidney health during spaceflight. We determined if: (1) plasma αKlotho was reduced after both spaceflight aboard the ISS and hindlimb unloading (HU); and (2) deficiency could be reversed with exercise. Both spaceflight and HU lowered circulating plasma αKlotho: plasma αKlotho recovered with exercise after HU.

2.
Endocrinol Metab Clin North Am ; 48(4): 859-873, 2019 12.
Artigo em Inglês | MEDLINE | ID: mdl-31655781

RESUMO

Untoward side effects of pharmaceuticals can result in considerable morbidity and expense to the health care system. There is likely a sizable fraction of the hypertensive population with disease either induced or exacerbated by polypharmacy. The elevation of blood pressure in drug-induced hypertension occurs through a variety of mechanisms, most notably, sodium and fluid retention, activation of the renin-angiotensin-aldosterone system, alteration of vascular tone, or a combination of these pathways. Recognition of common medications causing drug-induced hypertension is important to effectively control blood pressure. The epidemiology, pathophysiology, and management of these agents are discussed.


Assuntos
Inibidores da Angiogênese/efeitos adversos , Anti-Inflamatórios não Esteroides/efeitos adversos , Inibidores de Calcineurina/efeitos adversos , Estimulantes do Sistema Nervoso Central/efeitos adversos , Anticoncepcionais Orais Hormonais/efeitos adversos , Glucocorticoides/efeitos adversos , Hematínicos/efeitos adversos , Hipertensão/induzido quimicamente , Hipertensão/terapia , Polimedicação , Inibidores da Recaptação de Serotonina e Norepinefrina/efeitos adversos , Transtornos Relacionados ao Uso de Substâncias/complicações , Humanos
3.
Clin J Am Soc Nephrol ; 11(2): 262-70, 2016 Feb 05.
Artigo em Inglês | MEDLINE | ID: mdl-26668025

RESUMO

BACKGROUND AND OBJECTIVES: Prior studies have shown that the APOL1 risk alleles are associated with a greater risk of HIV-associated nephropathy and FSGS among blacks who are HIV positive. We sought to determine whether the APOL1 high-risk genotype incrementally improved the prediction of these underlying lesions beyond conventional clinical factors. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In a cross-sectional study, we analyzed data from 203 blacks who are HIV positive, underwent kidney biopsies between 1996 and 2011, and were genotyped for the APOL1 G1 and G2 alleles. Predictive logistic regression models with conventional clinical factors were compared with those that also included APOL1 genotype using receiver-operating curves and bootstrapping analyses with crossvalidation. RESULTS: The addition of APOL1 genotype to HIV-related risk factors for kidney disease in a predictive model improved the prediction of non-HIV-associated nephropathy FSGS, specifically, increasing the c statistic from 0.65 to 0.74 (P=0.04). Although two risk alleles were significantly associated with higher odds of HIV-associated nephropathy, APOL1 genotype did not add incrementally to the prediction of this specific histopathology. CONCLUSIONS: APOL1 genotype may provide additional diagnostic information to traditional clinical variables in predicting underlying FSGS spectrum lesions in blacks who are HIV positive. In contrast, although APOL1 risk genotype predicts HIV-associated nephropathy, it lacked a high c statistic sufficient for discrimination to eliminate the role of kidney biopsy in the clinical care of blacks who are HIV positive with nephrotic proteinuria or unexplained kidney disease.


Assuntos
Nefropatia Associada a AIDS/genética , Apolipoproteínas/genética , Negro ou Afro-Americano/genética , Glomerulosclerose Segmentar e Focal/genética , Infecções por HIV/genética , Rim/patologia , Lipoproteínas HDL/genética , Nefropatia Associada a AIDS/diagnóstico , Nefropatia Associada a AIDS/etnologia , Adulto , Apolipoproteína L1 , Biópsia , Distribuição de Qui-Quadrado , Estudos Transversais , Feminino , Predisposição Genética para Doença , Glomerulosclerose Segmentar e Focal/diagnóstico , Glomerulosclerose Segmentar e Focal/etnologia , Infecções por HIV/diagnóstico , Infecções por HIV/etnologia , Humanos , Modelos Logísticos , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Razão de Chances , Fenótipo , Valor Preditivo dos Testes , Estudos Retrospectivos , Medição de Risco , Fatores de Risco
4.
Clin J Am Soc Nephrol ; 8(9): 1524-32, 2013 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-23685946

RESUMO

BACKGROUND AND OBJECTIVES: HIV-associated nephropathy (HIVAN) is well described, but the clinical features of a group of renal pathologies characterized by Ig or immune complex depositions referred to as HIV-associated immune complex kidney disease (HIVICK) have not been well established. The objective of this study is to assess risk factors for HIVICK compared with contemporaneous control participants. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A nested case-control study of 751 HIV-infected patients followed from January 1996 to June 2010 was conducted. Groups were compared using the chi-squared test or rank-sum analysis. Conditional logistic regression was used to estimate odds ratios (ORs) for HIVICK. Incidences of overall ESRD and with/without combined antiretroviral therapy (cART) exposure were calculated. RESULTS: HIVICK patients were predominantly African American (92%). Compared with matched controls, patients with HIVICK were more likely to have HIV RNA >400 copies/ml (OR, 2.5; 95% confidence interval [95% CI], 1.2 to 5.2), diabetes (OR, 2.8; 95% CI, 1.1 to 6.8), and hypertension (OR, 2.3; 95% CI, 1.2 to 4.5). Compared with HIVAN, patients with HIVICK had more antiretroviral therapy exposure, lower HIV viral loads, and higher CD4 and estimated GFR. ESRD was less common in the HIVICK versus the HIVAN group (30% versus 82%; P<0.001), and the use of cART was not associated with ESRD in HIVICK patients (25% versus 26; P=0.39). CONCLUSIONS: HIVICK was predominantly observed in African-American patients and associated with advanced HIV disease. ESRD incidence is lower in HIVICK patients compared with those with HIVAN. Unlike HIVAN, cART use was not associated with the incidence of ESRD in HIVICK.


Assuntos
Nefropatia Associada a AIDS/virologia , Doenças do Complexo Imune/virologia , Falência Renal Crônica/virologia , Nefropatia Associada a AIDS/complicações , Nefropatia Associada a AIDS/tratamento farmacológico , Nefropatia Associada a AIDS/fisiopatologia , Adulto , Negro ou Afro-Americano , Antirretrovirais/uso terapêutico , Contagem de Linfócito CD4 , Estudos de Casos e Controles , Complicações do Diabetes , Progressão da Doença , Feminino , Taxa de Filtração Glomerular , HIV/genética , Humanos , Hipertensão/complicações , Doenças do Complexo Imune/complicações , Doenças do Complexo Imune/tratamento farmacológico , Doenças do Complexo Imune/fisiopatologia , Nefropatias/complicações , Nefropatias/fisiopatologia , Nefropatias/virologia , Masculino , Pessoa de Meia-Idade , RNA Viral/sangue , Fatores de Risco , Estados Unidos , Carga Viral
5.
Kidney Int ; 82(3): 338-43, 2012 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-22495294

RESUMO

Recently, an association was found between nondiabetic kidney disease in African Americans and two independent sequence variants in the APOL1 gene, encoding apolipoprotein L1. In this study we determined the frequency of APOL1 risk variants in patients with biopsy-proven HIV-associated nephropathy (HIVAN) and distinctive pathological characteristics potentially driven by those risk variants. Among 76 patients with HIVAN, 60 were successfully genotyped for APOL1 G1 and G2 polymorphisms. In this cohort, 37 had two risk alleles, 18 were heterozygous, and 5 had neither risk variant. There were no differences in the pathological findings of HIVAN and the number of APOL1 risk alleles. Further, the progression to end-stage kidney disease or death did not differ by the number of risk alleles. Median renal survival was 9.3 months in patients with zero or one risk allele compared to 11.7 months in patients with two APOL1 risk alleles. Thus, our study suggests that although the majority of African-American patients with HIVAN have two APOL1 risk alleles other as yet unknown factors in the host, including genetic risk variants and environmental or viral factors, may influence the development of this disorder in those with zero or one APOL1 risk allele.


Assuntos
Nefropatia Associada a AIDS/genética , Apolipoproteínas/genética , Lipoproteínas HDL/genética , Nefropatia Associada a AIDS/mortalidade , Nefropatia Associada a AIDS/patologia , Adulto , Negro ou Afro-Americano/genética , Apolipoproteína L1 , Estudos de Coortes , Feminino , Frequência do Gene , Variação Genética , Humanos , Estimativa de Kaplan-Meier , Falência Renal Crônica/complicações , Falência Renal Crônica/genética , Falência Renal Crônica/mortalidade , Falência Renal Crônica/patologia , Masculino , Pessoa de Meia-Idade , Fatores de Risco
6.
Clin Vaccine Immunol ; 19(5): 820-2, 2012 May.
Artigo em Inglês | MEDLINE | ID: mdl-22441395

RESUMO

Screening with hepatitis B surface antigen (HBsAg) is highly recommended for at-risk individuals. Mutations in the HBsAg can result in an inability to detect the virus during routine screening. We describe a hemodialysis patient found to have high levels of hepatitis B virus (HBV) DNA and HBV antibody but negative HBsAg on two routine assays.


Assuntos
DNA Viral/sangue , Reações Falso-Negativas , Antígenos de Superfície da Hepatite B/sangue , Vírus da Hepatite B/isolamento & purificação , Hepatite B/diagnóstico , Hepatite B/virologia , Diálise Renal/efeitos adversos , Feminino , Anticorpos Anti-Hepatite B/sangue , Humanos , Pessoa de Meia-Idade , Estados Unidos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA